Protagenic Therapeutics Stock Today
| PTIX Stock | USD 0.65 0.04 6.56% |
Performance3 of 100
| Odds Of DistressOver 80
|
Protagenic Therapeutics is trading at 0.65 as of the 23rd of November 2024; that is 6.56 percent up since the beginning of the trading day. The stock's open price was 0.61. Protagenic Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Protagenic Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of May 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of January 2016 | Category Healthcare | Classification Health Care |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company has 6.79 M outstanding shares of which 89.12 K shares are at this time shorted by private and institutional investors with about 1.33 trading days to cover. More on Protagenic Therapeutics
Moving against Protagenic Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Protagenic Stock Highlights
| Chairman of the Board | Garo Armen | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsProtagenic Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Protagenic Therapeutics' financial leverage. It provides some insight into what part of Protagenic Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Protagenic Therapeutics (PTIX) is traded on NASDAQ Exchange in USA. It is located in 149 Fifth Avenue, New York, NY, United States, 10010 and employs 1 people. Protagenic Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.04 M. Protagenic Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.79 M outstanding shares of which 89.12 K shares are at this time shorted by private and institutional investors with about 1.33 trading days to cover.
Protagenic Therapeutics currently holds about 8.87 M in cash with (3.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51.
Check Protagenic Therapeutics Probability Of Bankruptcy
Ownership AllocationProtagenic Therapeutics holds 14.24 pct. of its outstanding shares held by insiders and 5.76 pct. owned by third-party entities.
Check Protagenic Ownership Details
Protagenic Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Vanguard Group Inc | 2024-09-30 | 33.2 K | |
| Eagle Asset Management, Inc. | 2024-06-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-06-30 | 29.1 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 26.6 K | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 21.4 K | |
| Fny Investment Advisers, Llc | 2024-06-30 | 18.8 K | |
| State Street Corp | 2024-06-30 | 13.8 K | |
| Ubs Group Ag | 2024-06-30 | 10.1 K | |
| Tower Research Capital Llc | 2024-06-30 | 6.8 K | |
| Bank Of America Corp | 2024-06-30 | 29.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.0 |
Protagenic Therapeutics Historical Income Statement
Protagenic Stock Against Markets
Protagenic Therapeutics Corporate Executives
Elected by the shareholders, the Protagenic Therapeutics' board of directors comprises two types of representatives: Protagenic Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protagenic. The board's role is to monitor Protagenic Therapeutics' management team and ensure that shareholders' interests are well served. Protagenic Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protagenic Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.